Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALESSE vs A-METHAPRED
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol and levonorgestrel suppresses gonadotropin-releasing hormone (Gn RH) secretion from the hypothalamus, inhibiting pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby preventing ovulation. Additionally, it thickens cervical mucus, impeding sperm penetration, and alters endometrial receptivity.
Methylprednisolone is a synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators such as cytokines, prostaglandins, and leukotrienes. It also induces lipocortin synthesis, inhibits phospholipase A2, and reduces immune cell activity.
Prevention of pregnancy,Treatment of moderate acne vulgaris (in women ≥15 years who have achieved menarche and desire contraception),Contraception in women with heavy menstrual bleeding (off-label)
Allergic reactions (severe or disabling),Dermatologic diseases (e.g., pemphigus, exfoliative dermatitis),Endocrine disorders (e.g., congenital adrenal hyperplasia, nonsuppurative thyroiditis),Gastrointestinal diseases (e.g., ulcerative colitis, Crohn's disease),Hematologic disorders (e.g., autoimmune hemolytic anemia, thrombocytopenia),Neoplastic diseases (e.g., leukemia, lymphoma),Nervous system disorders (e.g., multiple sclerosis exacerbations),Ophthalmic diseases (e.g., allergic conjunctivitis, optic neuritis),Renal diseases (e.g., nephrotic syndrome, lupus nephritis),Respiratory diseases (e.g., asthma exacerbations, sarcoidosis),Rheumatic disorders (e.g., rheumatoid arthritis, acute gouty arthritis),Organ transplantation (as part of immunosuppressive regimen)
One tablet (ethinyl estradiol 20 mcg, levonorgestrel 0.1 mg) orally once daily at the same time each day for 21 days, followed by 7 days of placebo. For initiation, start on the first day of menstrual period or first Sunday after onset of menses.
Initial 4-48 mg/day oral in divided doses, tapered. For pulse therapy: 1 g IV daily for 3 days.
Levonorgestrel: terminal half-life ~17-20 hours (range 11-25 hr). Ethinyl estradiol: biphasic; terminal half-life ~13-27 hours (mean ~17 hr). Clinical context: steady-state achieved within 5-7 days. The half-life supports once-daily dosing with at least 24-hour contraceptive coverage.
2-3 hours (terminal); clinical effect persists longer due to intracellular receptor binding.
Ethinyl estradiol is primarily metabolized by CYP3A4 and undergoes conjugation (glucuronidation and sulfation). Levonorgestrel is metabolized by CYP3A4 and reduction, with conjugation to glucuronide and sulfate conjugates.
Primarily hepatic via CYP3A4 enzyme system, with minor contributions from other pathways.
Renal: ethinyl estradiol (UE2) and levonorgestrel (LNG) metabolites primarily excreted in urine (UE2: ~40% as sulfate and glucuronide conjugates; LNG: ~25% as glucuronides). Fecal/biliary: ~40% (UE2) and ~45% (LNG) eliminated in feces via bile. Unchanged drug excretion is negligible.
Renal (mainly as inactive metabolites); <5% unchanged. Biliary/fecal excretion is minimal.
Levonorgestrel: 97-99% bound to albumin and sex hormone-binding globulin (SHBG). Ethinyl estradiol: 98-99% bound, primarily to albumin (98.5%), with minor binding to SHBG. Free fractions: LNG ~1%, UE2 ~1.0-1.5%.
74-90% bound primarily to corticosteroid-binding globulin (CBG) and albumin.
Levonorgestrel: Vd ~1.8 L/kg (range 1.5-2.0 L/kg). Ethinyl estradiol: Vd ~2.5-3.5 L/kg (mean ~2.9 L/kg). Indicates extensive tissue distribution, including target organs (ovaries, endometrium, breast). Not clinically adjusted for obesity.
1.0-1.5 L/kg; indicates extensive tissue distribution.
Oral: levonorgestrel ~95-100% (highly bioavailable). Ethinyl estradiol ~45-55% (first-pass metabolism reduces bioavailability; interindividual variability due to gut wall and hepatic conjugation). Both are prodrugs requiring hydrolysis for activity.
Oral: ~80%; IM: ~100%.
No specific GFR-based dose adjustments are recommended; however, use with caution in patients with renal impairment due to potential fluid retention and hypertension.
No specific dose adjustment required; use caution in severe renal impairment.
Contraindicated in patients with severe hepatic disease (Child-Pugh class C) or active liver disease. In mild to moderate impairment (Child-Pugh A or B), use only if benefits outweigh risks; no specific dose reduction guidelines are available.
No specific guidelines; caution in severe hepatic impairment.
Approved for postmenarchal adolescents; same dosing as adults: one tablet orally once daily for 21 days followed by 7 days of placebo. No weight-based adjustments are recommended.
0.5-1.7 mg/kg/day or 5-25 mg/m²/day in divided doses.
Not indicated for use in postmenopausal women; no specific geriatric dosing adjustments are necessary if used off-label, but consider increased risk of thrombotic events in older women.
Lower initial doses recommended due to increased risk of osteoporosis, fluid retention, and immunosuppression.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. The risk increases with age, particularly in women over 35 years, and with heavy smoking (≥15 cigarettes per day). Women over 35 who smoke should not use this medication.
Corticosteroids, including methylprednisolone, may cause immunosuppression and increase susceptibility to infections. Live or live attenuated vaccines are contraindicated in patients receiving immunosuppressive doses. Administration of live vaccines may cause disseminated infection.
Increased risk of thromboembolic disorders (venous and arterial),Cigarette smoking increases risk of cardiovascular events, especially in women over 35,Hepatic neoplasia (benign and malignant),Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Headache/migraine,Depression,Uterine bleeding irregularities,Ocular lesions (e.g., retinal thrombosis),Carcinoma of the breast and reproductive organs (close monitoring in current or history of breast cancer)
Increased risk of infections; monitor for signs of infection and avoid exposure to active infections.,Adrenal suppression may occur, especially with prolonged therapy; taper dosing gradually.,May cause fluid and electrolyte disturbances (e.g., sodium retention, potassium loss, hypertension).,Gastrointestinal perforation risk, especially in patients with inflammatory bowel disease or recent GI surgery.,Osteoporosis with long-term use.,Behavioral and mood disturbances (e.g., euphoria, depression, psychosis).,Cushing's syndrome with chronic use.,Exacerbation of diabetes mellitus, glaucoma, and cataracts.,High-dose therapy may cause acute myopathy, particularly in patients on neuromuscular blocking agents.
Breast cancer (current or history),Carcinoma of the endometrium or other estrogen-dependent neoplasia,Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Valvular heart disease with complications,Severe hypertension,Diabetes with vascular involvement,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known or suspected pregnancy,Active liver disease or impaired liver function,Undiagnosed abnormal uterine bleeding,Hypersensitivity to any component,Cigarette smoking in women over 35 years of age
Systemic fungal infections,Hypersensitivity to methylprednisolone or any component of the formulation,Administration of live or live attenuated vaccines in immunosuppressive doses,Idiopathic thrombocytopenic purpura (IM route only)
No specific food restrictions. Grapefruit juice may slightly increase ethinyl estradiol levels but not clinically significant. High-fat meals do not affect absorption. Avoid excessive alcohol as it may impair compliance.
Avoid grapefruit and grapefruit juice as they may increase methylprednisolone levels. Limit sodium intake to reduce fluid retention. Avoid alcohol due to increased risk of gastrointestinal bleeding. Maintain adequate calcium and vitamin D intake to prevent bone loss.
Pregnancy category X. Use contraindicated in pregnancy. First trimester exposure associated with cardiovascular defects (e.g., VSD), neural tube defects, and cleft lip/palate. Second and third trimester exposure may cause fetal adrenal suppression, hepatic dysfunction, and virilization of female genitalia due to progestin component (levonorgestrel). Increased risk of ectopic pregnancy if conception occurs during use.
First trimester: Corticosteroids are associated with a small increased risk of oral clefts (odds ratio ~1.5). Second and third trimesters: Chronic use may lead to fetal adrenal suppression, intrauterine growth restriction, and preterm birth. Risk is dose- and duration-dependent.
Excreted in breast milk. Levonorgestrel M/P ratio approximately 0.3–0.4. Small amounts of ethinyl estradiol present. May reduce milk production and quality due to estrogen component. Use only if benefit outweighs risk; consider alternative contraception. American Academy of Pediatrics considers it compatible with nursing.
Prednisolone (active metabolite) is excreted into breast milk, with an M/P ratio approximately 5:1 to 20:1. The relative infant dose is estimated at <10% of maternal weight-adjusted dose. Monitor infant for adrenal suppression and growth. Nursing should be timed 3-4 hours after maternal dose.
Contraindicated. No dose adjustments apply as drug must be discontinued immediately if pregnancy suspected or confirmed. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) not relevant due to contraindication.
Dose adjustment may be necessary due to increased clearance of prednisolone in pregnancy. Dose should be individualized, often with increased doses during pregnancy and reduced postpartum. No standard fixed adjustment; monitor clinical response.
ALESSE is a combined oral contraceptive (COC) containing ethinyl estradiol (20 mcg) and levonorgestrel (100 mcg). It is indicated for contraception and treatment of acne vulgaris in women aged ≥14. Monitor for thromboembolic events, especially in smokers >35 years. Assess for contraindications including migraines with aura, hypertension, and history of DVT/PE. Advise use of backup contraception if a pill is missed. Start on first day of menses or first Sunday after onset. Check BP at baseline and annually. Counsel on increased risk of VTE, especially in first year.
A-Methapred is a brand of methylprednisolone sodium succinate. For acute spinal cord injury, administer within 8 hours with a bolus of 30 mg/kg over 15 minutes, followed by a 45-minute pause, then 5.4 mg/kg/hour for 23 hours. Monitor for hyperglycemia, especially in diabetic patients; consider insulin sliding scale. Taper dose if used for >5 days to avoid adrenal insufficiency. Avoid abrupt discontinuation.
Take one pill daily at the same time each day, even if you do not have sex.,Missed pill instructions: if late by <12 hours, take it as soon as remembered and continue schedule. If >12 hours, take missed pill (even if means taking two in one day) and use backup contraception for 7 days.,Possible side effects: nausea, breast tenderness, headache, breakthrough bleeding, especially in first 3 months.,Seek emergency care for signs of blood clot: leg pain/swelling, sudden chest pain, shortness of breath, severe headache, vision changes.,Do not smoke while on ALESSE, especially if over age 35, as it increases risk of serious cardiovascular events.,Inform your healthcare provider of all medications and supplements you take, as some (e.g., rifampin, anticonvulsants, St. John's wort) may reduce effectiveness.
Do not stop taking this medication suddenly without consulting your doctor; dosage must be tapered gradually.,Report any signs of infection (fever, sore throat, cough) or unusual bleeding/bruising immediately.,Avoid live vaccines while on this medication.,Take with food or milk to reduce stomach upset.,Carry a medical alert card stating you are taking corticosteroids.,Do not miss doses; take exactly as prescribed.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALESSE vs A-METHAPRED, answered by our medical review team.
ALESSE is a Estrogen/Progestin Combination Contraceptive that works by Combination of ethinyl estradiol and levonorgestrel suppresses gonadotropin-releasing hormone (Gn RH) secretion from the hypothalamus, inhibiting pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby preventing ovulation. Additionally, it thickens cervical mucus, impeding sperm penetration, and alters endometrial receptivity.. A-METHAPRED is a Corticosteroid that works by Methylprednisolone is a synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators such as cytokines, prostaglandins, and leukotrienes. It also induces lipocortin synthesis, inhibits phospholipase A2, and reduces immune cell activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALESSE and A-METHAPRED depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALESSE is: One tablet (ethinyl estradiol 20 mcg, levonorgestrel 0.1 mg) orally once daily at the same time each day for 21 days, followed by 7 days of placebo. For initiation, start on the first day of menstrual period or first Sunday after onset of menses.. The standard adult dose of A-METHAPRED is: Initial 4-48 mg/day oral in divided doses, tapered. For pulse therapy: 1 g IV daily for 3 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALESSE and A-METHAPRED in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALESSE is classified as Category C. Pregnancy category X. Use contraindicated in pregnancy. First trimester exposure associated with cardiovascular defects (e.g., VSD), neural tube defects, and cleft lip/palate. Seco. A-METHAPRED is classified as Category C. First trimester: Corticosteroids are associated with a small increased risk of oral clefts (odds ratio ~1.5). Second and third trimesters: Chronic use may lead to fetal adrenal sup. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.